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The basal (ligand-independent) kinase activity of
receptor tyrosine kinases (RTKs) promotes trans-
phosphorylation on activation loop tyrosines upon
ligand-induced receptor dimerization, thus upregu-
lating intrinsic kinase activity and triggering intracel-
lular signaling. To understand the molecular determi-
nants of intrinsic kinase activity, we used X-ray
crystallography and NMR spectroscopy to analyze
pathogenic FGF receptor mutants with gradations
in gain-of-function activity. These structural analyses
revealed a ‘‘two-state’’ dynamic equilibrium model
whereby the kinase toggles between an ‘‘inhibited,’’
structurally rigid ground state and a more dynamic
and heterogeneous active state. The pathogenic
mutations have different abilities to shift this equilib-
rium toward the active state. The increase in the
fractional population of FGF receptors in the active
state correlates with the degree of gain-of-function
activity and clinical severity. Our data demonstrate
that the fractional population of RTKs in the active
state determines intrinsic kinase activity and under-
score how a slight increase in the active population
of kinases can have grave consequences for human
health.INTRODUCTION
Receptor tyrosine kinases (RTKs) regulate a myriad of biological
processes in mammalian development, tissue homeostasis, and
metabolism (Hunter, 2000; Lemmon and Schlessinger, 2010). At
basal state, RTKs possess low levels of intrinsic kinase activity.376 Cell Reports 4, 376–384, July 25, 2013 ª2013 The AuthorsThis basal activity plays a key role in RTK signal transduction
because it primes trans-phosphorylation of tyrosines in the
activation loop (A loop) upon ligand binding and receptor
dimerization resulting in full activation of the kinase. This in turn
allows tyrosine phosphorylation of the kinase insert and flanking
juxtamembrane and C-terminal tail regions of the RTKs. These
secondary phosphorylation events then serve to recruit down-
stream signaling substrates for tyrosine phosphorylation by the
activated RTK, culminating in activation of intracellular signaling
pathways.
The basal, intrinsic activity of RTKs must be carefully
balanced. Insufficient basal activity would diminish the ability
of ligand-induced dimerization to promote A loop tyrosine
trans-phosphorylation, and hence, signal transmission would
stall. Conversely, excess basal activity would bypass the
requirement for ligand-induced dimerization in kinase activation,
resulting in ligand-independent constitutive RTK signaling.
Indeed, kinase domain mutations that elevate or reduce the
intrinsic activity of RTKs are common culprits in a diverse array
of human diseases. An accumulatedwealth of structural and bio-
physical data has revealed some insight into the autoinhibitory
mechanisms that keep tyrosine kinase activity at bay (Hubbard,
2002) and has also elucidated the molecular basis of kinase acti-
vation by A loop tyrosine phosphorylation (Chen et al., 2007;
Hubbard and Till, 2000; Pellicena and Kuriyan, 2006; Rajakulen-
dran and Sicheri, 2010). Despite these major strides in under-
standing the mechanisms of kinase regulation, a fundamental
question has remained unanswered: what precisely determines
basal, intrinsic kinase activity?
In FGFR2 and FGFR3, a conserved lysine located two residues
away from the A loop tyrosines is a major hot spot codon for
pathogenic mutations. Substitutions of Lys650 in FGFR3 with
Thr, Asn, Gln, Met, or Glu cause dwarfism syndromes of varying
clinical severity (Vajo et al., 2000) (Figure S1). Among them,
neonatal lethal thanatophoric dysplasia type II (TDII) is the
most severe and is caused by the Lys650Glu mutation (Chen
Figure 1. Pathogenic Mutations at Lys650
of FGFR3 Impart Different Degrees of A
Loop Phosphorylation-Independent Kinase
Activation
(A) Fold increase in the activity of Lys650 mutants
andphosphorylated (Phos.)WTFGFR3kinaseover
the unphosphorylated (Unphos.)WTFGFR3kinase
measured at 30 s. Error bars represent mean ± SD.
(B) Analogous mutations targeting Lys659 in
FGFR2 kinase lead to a similar pattern of graded
kinase activation. The activities of the pathogenic
kinases are less than that of mono-phosphory-
lated FGFR2KpY657 (labeled as pY657), implying
that the mutations activate in a partially ligand-
independent fashion. Black and green bars
represent Tyr656/Tyr657 and Phe656/Phe657
versions of the kinases, respectively. Error bars
represent mean ± SD.
(C) Structure-based sequence alignment of the A
loop and the autoinhibitory molecular brake
among FGFR kinases. The A loop is boxed in blue.
The twin tyrosines and the lysine on the A loop and
the three components of the molecular brake are
labeled in orange, red, and green, respectively.
See also Figure S1.et al., 2001; Tavormina et al., 1995; Webster et al., 1996; Wilcox
et al., 1998). Substitution of Lys650 with Met causes severe
achondroplasia with developmental delay and acanthosis nigri-
cans (SADDAN) syndrome (Bellus et al., 1999; Tavormina et al.,
1999). The Lys650Asn and Lys650Gln mutations lead to hypo-
chondroplasia (HCH), a mild form of dwarfism (Bellus et al.,
1995, 2000). The Lys650Thr mutation causes an even milder
form of HCH (Berk et al., 2007; Castro-Feijo´o et al., 2008).
In vitro autophosphorylation assays have shown that these mu-
tations confer different degrees of ligand-independent activation
on FGFR kinase and that the degree of aberrant activation corre-
lates with the clinical severity of the dwarfism syndromes caused
by the mutations (Bellus et al., 2000). This naturally occurring set
of pathogenic kinases with graded kinase activity provides a
powerful tool to explore the molecular determinants of intrinsic
kinase activity. In this report, we studied the impact of these
five pathogenic mutations on the structure and dynamics of
FGFR kinase using X-ray crystallography and NMR spectros-
copy. Our data uncover a ‘‘two-state’’ dynamic equilibrium
model for regulation of FGFR kinase and likely other RTKs and
show that the fractional population of the kinase in the active
state determines intrinsic kinase activity.
RESULTS AND DISCUSSION
Pathogenic Mutations of Lys650/Lys659 of FGFR3/
FGFR2 Elevate Intrinsic Kinase Activity of FGFR
Independent of A Loop Tyrosine Phosphorylation
Bellus and colleagues (Bellus et al., 2000) were the first to study
the impact of the dwarfism syndromemutations at Lys650 on the
kinase activity of FGFR3 and noticed a functional-clinical corre-
lation between the degree of gain of function and severity of
skeletal phenotypes (Figure S1). In their study, wild-type (WT)
full-length FGFR3 and its mutants harboring the pathogenic
substitutions at Lys650 were overexpressed in mammalian cells,and the activities of immunopurified receptors were compared
using an in vitro autophosphorylation assay. This approach has
two limitations, however. First, due to the activating nature of
these mutations, the overexpressed receptor mutants may
contain residual A loop tyrosine phosphorylation, which would
confound conclusions about the kinase assay data. Second,
measuring intrinsic kinase activity using autophosphorylation
can be potentially misleading because the mutations could
affect the latter in the absence of an effect on kinase activity.
To unambiguously determine the impact of the pathogenic
mutations on the intrinsic kinase activity of FGFR3 kinase, we
purified phosphorylation-free WT and mutated FGFR3 kinase
domains and compared their intrinsic activities using a substrate
phosphorylation assay. Our kinase assay data show that the
mutations differentially enhance the intrinsic activity of FGFR3
kinase in the following order: Lys650Glu > Lys650Met >
Lys650Asn  Lys650Gln > Lys650Thr (Figure 1A). This trend is
generally in agreement with the data reported by Bellus and
colleagues (Bellus et al., 2000) except that in this previous study,
Lys650Met showed greater autophosphorylation activity than
Lys650Glu, which is inconsistent with the clinical severity of
the dwarfism syndromes caused by these mutations.
Having confirmed the gradation in gain of function imparted by
the different pathogenic mutations, we next examined the struc-
tural basis of graded kinase activation by the pathogenic muta-
tions. Because comprehensive structural studies of this scale
require an abundant source of protein, we decided to use the
highly homologous FGFR2 kinase as the ‘‘workhorse’’ for this
study because it can be expressed at higher levels in E. coli
than the FGFR3 kinase. FGFR2 and FGFR3 kinases share 82%
overall sequence identity, with 86% identity within the A loop,
and both are regulated by the FGFR-invariant molecular brake
at the kinase hinge region (Chen et al., 2007) (Figure 1C). Indeed,
Lys659 (corresponding to Lys650 in FGFR3) and molecular
brake mutations in FGFR2 kinase lead to gain of function inCell Reports 4, 376–384, July 25, 2013 ª2013 The Authors 377
Table 1. X-Ray Data Collection and Refinement Statistics
Construct K659E K659M K659N K659Q K659T
Data Collection
Resolution (A˚)a 50–2.6 (2.69–2.6) 50–2.3 (2.34–2.3) 50–2.4 (2.44–2.4) 50–2.3 (2.34–2.3) 50–1.85 (1.88–1.85)
Space group P1 P4322 C2 P4322 C2
Unit cell parameter: a (A˚) 70.584 73.852 278.634 73.785 278.508
Unit cell parameter: b (A˚) 70.278 73.852 78.122 73.785 78.395
Unit cell parameter: c (A˚) 85.499 310.716 72.791 313.749 73.197
Unit cell parameter: a () 92.39 90.00 90.00 90.00 90.00
Unit cell parameter: b () 112.19 90.00 101.90 90.00 101.02
Unit cell parameter: g () 115.98 90.00 90.00 90.00 90.00
Content of the asymmetric unit 4 2 4 2 4
Number of measured reflections 147,245 1,028,351 453,471 258,430 453,556
Number of unique reflections 41,786 39,689 60,839 38,222 127,643
Data redundancy 3.5 25.9 7.5 6.8 3.6
Data completeness (%)a 97.1 (84.5) 99.8 (100.0) 99.4 (99.3) 96.6 (99.8) 96.4 (89.4)
Rsym (%)
a,b 7.4 (33.2) 11.4 (49.8) 5.9 (41.7) 11.8 (35.5) 3.1 (31.9)
I/sig 24.5 43.6 50.8 33.6 45.0
Refinement
R factor/Rfree 18.0/26.1 18.0/21.8 20.6/26.1 18.6/23.7 22.1/24.9
Number of protein atoms 9,011 4,838 8,709 4,818 8,996
Number of nonprotein/solvent atoms 141 78 139 51 149
Number of solvent atoms 135 190 90 229 397
Rmsd bond length (A˚) 0.014 0.008 0.009 0.008 0.007
Rmsd bond angle () 1.567 1.132 1.201 1.170 1.153
PDB ID 4J97 4J96 4J95 4J98 4J99
aNumbers in parentheses refer to the highest resolution shell.
bRsym =
PjI hIij=P I, where I is the observed intensity of a reflection, and hIi is the average intensity of all the symmetry-related reflections.craniosynostosis syndromes (Kan et al., 2002), endometrial
cancer (Pollock et al., 2007), and cervical cancer (Dutt et al.,
2008). As expected, our substrate phosphorylation assay data
show that the correspondingmutations in FGFR2 kinase, namely
Lys659Glu, Lys659Met, Lys659Asn, Lys659Gln, and Lys659Thr,
behave similarly and impart graded kinase activation following
the same order as determined for FGFR3 kinase (Figures 1A
and 1B). Notably, the data also show that the intrinsic activities
of the pathogenic FGFR2 kinases are lower than that of FGFR2
kinase activated by A loop phosphorylation (FGFR2KpY657),
indicating that these pathogenic mutations activate the kinase
in a partially ligand-independent fashion. These ‘‘pathogenic’’
FGFR2 kinases were then crystallized in the presence of a non-
hydrolyzable ATP analog (AMP-PCP) andMgCl2, and their struc-
tures were determined. Data collection and refinement statistics
are summarized in Table 1.
Comparison of the crystal structures of the pathogenic FGFR2
kinases with those of unphosphorylated and A loop phosphory-
lated WT FGFR2 kinases reveals that all five mutants adopt the
same active conformation, reminiscent of the phosphorylated
WT kinase (Figures 2A and 2B). In each structure, the side chain
of the mutated residue makes novel contacts with nearby resi-
dues, thus locally stabilizing an active A loop conformation. The
rearranged A loop engages in favorable intramolecular contacts
with theaChelix in theN lobe leading to closer apposition of theN378 Cell Reports 4, 376–384, July 25, 2013 ª2013 The Authorsand C lobe and disengagement of the molecular brake at the
kinase hinge region, which allows the kinase to adopt the active
conformation. In the Lys659Met mutant structure, the side chain
of Met659 binds a hydrophobic depression formed by Leu665,
Met670, Ala674, Tyr680, andTyr657, the latter ofwhich is located
in the A loop (Figure 2C). In the remaining four mutant structures
(Figures 2D–2G), the side chains of themutated residues engage
in hydrogen bonding with Arg625 in the catalytic loop. Moreover,
in each of these four structures, the oxygen atoms from the
side chains of the mutated residues participate in oxygen-
aromatic interactions with Tyr657 in the A loop. In all five mutant
structures, Tyr657 occupies a position similar to the phosphory-
lated Tyr657 in the activated WT kinase structure and makes a
direct hydrogen bond with Arg649, which further supports an
active A loop conformation. These data unambiguously demon-
strate that the pathogenicmutations simulate an activated A loop
conformation (Figure 2B). To ensure that the mechanism of
activation observed in the FGFR2 kinase mutant structures truly
reflects the effect of the actual pathogenic FGFR3 kinase muta-
tions, we have solved the crystal structure of FGFR3 kinase
harboring the Lys650Glu mutation. Similar to the Lys659Glu
FGFR2 kinase structure, the carboxylate side chain of Glu650 en-
gages in hydrogen bonding with Arg616 in the catalytic loop,
while simultaneously participating in oxygen-aromatic interac-
tions with Tyr648. These intramolecular interactions result in
Figure 2. FGFR2 Kinase Lys659 Mutations
Have Different Capacities to Stabilize the
Active State Conformation of the A Loop
(A) Comparison of the A loop conformations of
unphosphorylated WT (in black, PDB ID 2PSQ;
Chen et al., 2007), phosphorylatedWT (in red, PDB
ID 2PVF; Chen et al., 2007), Lys659Glu mutant (in
blue, PDB ID 4J97), Lys659Met mutant (in purple,
PDB ID 4J96), Lys659Gln mutant (in orange, PDB
ID 4J98), Lys659Asn mutant (in green, PDB ID
4J95), and Lsy659Thr mutant (in cyan, PDB ID
4J99) FGFR2 kinase structures. Asp644 and
Pro666 lie at the beginning and end of the A loop
and are indicated in the unphosphorylated WT ki-
nase structure. The subtle difference in the C-ter-
minal region of the A loop between the phosphor-
ylated WT kinase and the unphosphorylated WT
and mutant kinases is due to an interaction
between this section of the A loop and substrate
peptide (which is not present in any of the un-
phosphorylatedWTandmutant kinase structures).
(B) Close-up view of intramolecular interactions
introduced by A loop tyrosine phosphorylation
(Chen et al., 2008).
(C–G) Close-up view of intramolecular interactions
introduced by the Lys659 mutations. The mutant
residues are labeled in red. Side chains of
selected residues are shown as sticks. Atom
colorings are as follows: oxygens are in red, ni-
trogens in blue, phosphorus in yellow, and car-
bons in green. The hydrogen bonds and oxygen
aromatic interactions are shown as dashed lines
with distance (in A˚) labeled alongside in black and
red, respectively. The hydrophobic interactions
are represented by semitransparent surfaces.stabilization of the A loop in the active conformation (Z.H., H.C.,
and M.M., unpublished data). To validate the mechanism of
activation observed in the crystal structures of FGFR2 kinase
mutants, the effects of mutating A loop tyrosines (Tyr656 and
Tyr657) to phenylalanine were studied. The data show that elim-
ination of A loop tyrosine phosphorylation only modestly reduces
the activity of the pathogenic kinases (Figure 1B), which is
consistent with the direct involvement of Tyr657 in the stabiliza-
tion of an A loop active conformation (Figures 2C–2G).
A Two-State Dynamic Equilibrium Model Underlies
FGFR Kinase Regulation
The structural data showing that all five pathogenic mutations
stabilize the same active conformation as A loop tyrosine phos-Cell Reports 4, 376–phorylation does in the WT kinase are
surprising given the differences in the in-
trinsic activity of the mutant kinases and
the mono-phosphorylated FGFR2KpY657.
Close inspection of the intramolecular
contacts introduced by the different path-
ogenic mutations, however, unveils the
molecular basis for the observed grada-
tions in kinase activity of the mutants.
The analysis shows a direct correlation
between the number and length ofhydrogen bonds and oxygen-aromatic interactions that each
mutation introduces (summarized in Table S1) and the degree
of gain in intrinsic kinase activity imparted by that mutation.
This is best illustrated by comparing the structures of the most
active mutant (Lys659Glu, Figure 2D) and the least active mutant
(Lys659Thr, Figure 2G). In the Lys659Glu structure, the carbox-
ylate side chain of Glu659 introduces a total of three strong
hydrogen bonds (%3 A˚) with Arg625 and two oxygen-aromatic
interactions (%3 A˚) with Tyr657. In contrast, the Lys659Thr struc-
ture shows that Thr659makes only a single weak hydrogen bond
(>3 A˚) with Arg625 and two oxygen-aromatic interactions
(>3.5 A˚) with Tyr657. Hence, these static crystallographic snap-
shots imply that the pathogenic mutations have different poten-
tials to stabilize the same active conformation of the enzyme.384, July 25, 2013 ª2013 The Authors 379
Figure 3. HSQC Chemical Shift Perturba-
tion Plotted as a Function of Residue for
the Mutants and the Mono-Phosphorylated
FGFR2KpY657
Dd was calculated according to Equation 1
between the unphosphorylated WT kinase and the
kinases indicated in the figure. These data were
used to construct Figure S3.
See also Figures S2 and S3.Taken together with the observed gradations in kinase activity,
these X-ray crystallographic data led us to propose that FGFR
kinase exists in dynamic exchange between an inhibited ground
state conformation and an active state conformation and that
the mutations act by increasing the population of kinase mole-
cules in the active state. Accordingly, the fractional population
of kinase molecules in the active state determines the intrinsic
kinase activity.
To test this hypothesis, we employed NMR spectroscopy to
investigate the effects of the mutations on the conformation
and dynamics of FGFR2 kinase in solution. As expected, the
overlay of HSQC spectra showed large chemical shift changes
for many residues between unphosphorylated WT kinase and
the mono-phosphorylated kinase, FGFR2KpY657 (Figure S2).
Importantly, many residues in the kinase mutants also experi-
enced chemical shift changes. Mapping of these perturbations
onto the crystal structure of unphosphorylated WT FGFR2
kinase shows that the pathogenic mutations affected a similar
set of residues as those perturbed by Tyr657 phosphorylation
(Figures 3 and S3). Interestingly, several residues of the patho-380 Cell Reports 4, 376–384, July 25, 2013 ª2013 The Authorsgenic kinases show chemical shifts that
fall between those of the unphosphory-
latedWT kinase and themono-phosphor-
ylated FGFR2KpY657 along a straight,
linear trajectory (Figures 4A and S4).
Notably, the HSQC spectra for the un-
phosphorylated WT kinase and all five
pathogenic mutant kinases contain a
relatively narrow peak for each residue,
indicating a fast chemical exchange
with the two endpoints of the chemical
shifts defined by the unphosphorylated
low-activity state and the mono-phos-
phorylated (pY657) active state. Further-
more, the assigned chemical shifts of
the most active mutant kinase, namely
Lys659Glu, are the closest to those
of the mono-phosphorylated kinase,
FGFR2KpY657, whereas the assigned
chemical shifts of the least active mutant
kinase, namely Lys659Thr, are the
closest to those of the unphosphorylated
WT kinase (Figure 4A). This spectral
behavior of these pathogenic kinases
strongly suggests that these mutants
differentially sample a common equilib-
rium between a structural state resem-bling the unphosphorylated inhibited state and another
resembling the A loop phosphorylated active state. Based on
the positions of NMR chemical shifts for the five pathogenic
kinases, and on the assumption that the unphosphorylated and
A loop phosphorylated FGFR2 kinases represent the pure
ground state and the active state, respectively, in a fast two-
state conformational exchange regime, the fractional population
of kinase molecules occupying the active state was calculated
for each mutant (Figure 4B). This approach has been previously
used to study the impact of engineered gain- and loss-of-
function mutations on the fractional populations of nitrogen
regulatory protein C (NtrC) (Volkman et al., 2001) and guanine
nucleotide exchange factor Vav1 (Li et al., 2008) in the active
state. Using the populations derived from Figure 4B and the
normalized activity values from Figure 1B, a quantitative correla-
tion plot was constructed (Figure 4C). The strong correlation (r2 =
0.97) reveals a direct relationship between an increase in popu-
lation of kinase molecules in the active state and the degree of
gain of function. These data support the two-state model and
show that the pathogenic mutations act by altering the intrinsic
Figure 4. NMRChemical Shift Spectra for the UnphosphorylatedWT
FGFR2 Kinase, Unphosphorylated Pathogenic FGFR2 Kinases, and
Mono-Phosphorylated FGFR2KpY657
(A) Selected peaks in the [1H,15N] HSQC spectra showing linear chemical shift
changes.
(B) The population of active state for each mutant, assuming that the
unphosphorylated WT FGFR2 kinase and the mono-phosphorylated
FGFR2KpY657 respectively represent the pure basal and active states in a fast
two-state conformational exchange regime.
(C) Correlation plot of the normalized kinase activity versus the active state
population calculated from the NMR chemical shifts. The NMR spectra and
correlation plot are color coded for each sample as indicated in (B).
See also Figures S4 and S5.
Figure 5. A Two-State Dynamic Equilibrium Model for FGFR Kinase
Regulation Deduced from the Structural and Biochemical Data
Generated in This Study
In this model, FGFR kinase toggles between an ‘‘inhibited’’ and conforma-
tionally rigid ground state, and a more dynamic and heterogeneous ‘‘active’’
state.
(A) Under physiological conditions, FGFR kinases primarily populate the in-
hibited ground state with only a small fraction of kinases capable of adopting
the active state. The pathogenic gain-of-function mutations enable the kinase
to more readily attain and reside longer in the active state, thus increasing the
overall population of the kinases in the active state. According to this model,
the more activating the mutation is, the more the equilibrium is skewed toward
the active state. This model explains the molecular basis of the correlation
between the degree of gain of function and the severity of clinical manifestation
associated with these mutations.
(B) Compared to the structurally rigid kinases in the inhibited ground state, the
active state kinases are conformationally more dynamic.
(C) Consistent with the conformational heterogeneity within the active state,
kinases in the active state are in the rugged elevated energy state, whereas the
kinases in the ground state are in the low-resting energy state.
See also Figures S5, S6, and S7.conformational dynamics of the kinase to favor the active state
(Figure 5).
Free-Energy Landscape of FGFR Kinase Is Biased
Toward the Inactive State
Interestingly, the HSQC spectrum of the A loop phosphorylated
kinase shows broader peaks for several residues within the cat-
alytic loop that display linear chemical shift changes in the
mutated kinases (Figure S5). This spectral behavior implies that
compared with the inactive state, the active state is more
dynamic (Figure 5B). Consistent with this observation, 15N{1H}
R2 NMR spin relaxation data on the unphosphorylated WT
kinase, the pY657 mono-phosphorylated kinase, and unphos-
phorylated mutant kinases revealed that, akin to A loop phos-
phorylation, the gain-of-function mutations lead to increases in
R2 consistent with greater conformational flexibility (Figure S6).
Taken together, these findings suggest the presence of con-
formational heterogeneity in the active state arising from an
elevated energy landscape compared with the low-energy stateof the kinases in the ground state (Figure 5C). The high level of
free-energy associated with the active state is harmonious with
the fact that the unphosphorylated WT kinase has never been
crystallized in the active state and suggests that the gain-of-func-
tionmutations cause an increase in the population of active state
molecules that is sufficient to enable crystallization of the kinase
in the active state. The instability of the active state also explains
why the isolated phosphorylated FGFR kinase tends to dephos-
phorylate over time (H.C. and M.M., unpublished data).Cell Reports 4, 376–384, July 25, 2013 ª2013 The Authors 381
Notably, the two-state model underlying FGFR kinase regula-
tion differs from the conventional two-basin free-energy land-
scape model proposed for Src and CDK2 kinases (Banavali
and Roux, 2009; Berteotti et al., 2009), in which the active state
forms a well-defined low-energy basin that is separated by a
high-energy barrier from the inactive state (high-energy basin)
(Figure S7A). However, our findings are concordant with the
NMR spectroscopy and MD simulation data showing that the
phosphorylated apo form of protein kinase A exists in a ‘‘dynam-
ically uncommitted state’’ characterized by the presence of inho-
mogeneous line broadening in several loops (Masterson et al.,
2011). In the case of the EGFR kinase, molecular dynamics simu-
lation experiments have led to the postulation of a distinct three-
state energy landscape model in which a third ‘‘disordered’’
state forms a low-energy basin intervening between the inactive
and active states (Shan et al., 2012) (Figure S7B). Similar to the
FGFR kinase, the active state of the EGFR kinase also possesses
a higher level of free-energy and lacks the typical energy basins
seen in Src and CDK2 kinases.Concluding Remarks
Our X-ray crystallographic and NMR data reveal a direct correla-
tion between gradations of intrinsic kinase activity and a shift in
the equilibrium toward the active conformation of the kinase,
thus demonstrating that the fractional population of enzyme in
an activated state determines the intrinsic activity. We suggest
that the two-state dynamic equilibrium model, uncovered here
for the regulation of the class IV FGFR kinase family, is also appli-
cable to kinases of the class III RTK subfamily. The three constit-
uents of themolecular brake are fully conserved in class III RTKs,
namely PDGFRs, C-KIT, C-FMS, and VEGFRs. In addition,
molecular brake mutations in PDGFR and VEGFR also lead to
receptor activation and human malignancies (Corless et al.,
2005; Medeiros et al., 2004). Moreover, selective ATP-competi-
tive inhibitors of VEGFR and PDGFR often cross-inhibit FGFR
kinases (Renhowe et al., 2009), and pathogenic activating muta-
tions in class III RTKs, when grafted into FGFR kinases, confer
gain of function (M.M., unpublished data). In conclusion, our
data demonstrate that pathogenic mutations act by corrupting
the intrinsic conformational dynamics of the kinase to favor the
active state, and allow us to draw an elegant correlation between
the increase in population of RTK molecules in the active state
and the degree of severity in clinical phenotype. In addition to
underscoring the importance of tightly controlled regulation of
intrinsic RTK activity in human biology, our data provide frame-
works for the rational design of inhibitors to tame these hyperac-
tive pathogenic FGFRs for treating human diseases. Finally, our
data inform us of innovative strategies for better clinical manage-
ment of human skeletal disorders by suggesting that the dosage
of inhibitors should be adjusted to the degree by which muta-
tions push the kinase into the active conformation.EXPERIMENTAL PROCEDURES
Protein Expression, Purification, and Crystallization
The cDNA fragments encoding residues Pro449 to Glu759 of human FGFR3c
(accession code P22607-1) and Pro458 to Glu768 of human FGFR2c (acces-
sion code P21802-1) were amplified by PCR and subcloned into a pET bacte-382 Cell Reports 4, 376–384, July 25, 2013 ª2013 The Authorsrial expression vector with an NH2-terminal 63his tag to aid in protein purifica-
tion. All the mutations were introduced using the QuikChange Site-Directed
Mutagenesis Kit (Stratagene). The bacterial strain BL21(DE3) cells were trans-
formed with the expression constructs, and kinase expression was induced
with 1 mM isopropyl-L-thio-B-D-galactopyranoside overnight at 16C–25C
depending on the construct. The cells were lysed, and the soluble kinase pro-
teins were purified according to the published protocol (Chen et al., 2007).
Traces of phosphorylation on WT and mutant kinases were removed by treat-
ing the proteins with FastAP Thermosensitive Alkaline Phosphatase (Thermo
Scientific) and the kinases were repurified by anion exchange chromatography
(Mono Q; GE Healthcare Life Sciences). The FGFR2 kinase constructs contain
five tyrosine autophosphorylation sites, namely Tyr466 in the juxtamembrane
region, Tyr586 and Tyr588 in the kinase insert, and Tyr656 and Tyr657 in the A
loop. Of these, phosphorylation on the A loop Tyr657 is sufficient for kinase
activation. Because making large quantities of homogeneously penta-phos-
phorylated FGFR2 kinase sample proved to be challenging, Tyr466, Tyr586,
Tyr588, and Tyr656 were mutated to the corresponding nonphosphorylatable
residues in FGFR4 kinases (Tyr586Leu and Tyr588Pro) or phenylalanine
(Tyr466Phe and Tyr656Phe). This construct (FGFR2KY657) was purified in
the same fashion as the WT FGFR2 kinase construct and was phosphory-
lated on Tyr657 by incubating it with ATP and MgCl2. The homogeneously
mono-phosphorylated kinase (FGFR2KpY657) was isolated by size exclusion
chromatography followed by anion exchange chromatography. N-terminally
His-tagged substrate peptide consisting of residues Leu761 to Thr821 of
FGFR2c was expressed and purified using sequential Ni2+ chelating and
size exclusion chromatographies. The substrate peptide corresponds to the
C-terminal tail of FGFR2 and contains five authentic tyrosine phosphorylation
sites: Tyr769, Tyr779, Tyr783, Tyr805, and Tyr812. Isotopically labeledWT and
pathogenic kinases were expressed and purified similar to their unlabeled
counterparts.
Protein Crystallization
The purified FGFR2 kinasemutants were concentrated to about 10–100mg/ml
using Amicon Ultra-4 10K Centrifugal Filters (Millipore). Prior to crystallization,
the pathogenic kinases were mixed with ATP analog (AMP-PCP) and MgCl2 at
a molar ratio of 1:3:15. Initial crystals of pathogenic kinases were grown by
hanging drop vapor diffusion at 20C using crystallization buffer composed
of 25 mM HEPES (pH 7.5), 15%–25% w/v PEG4000, 0.2–0.3 M NH4SO3,
and were further optimized by appropriate additives.
X-Ray Data Collection and Structure Determination
Diffraction data were collected on single cryo-cooled crystals at beamlines
X-4A and X-4C at the National Synchrotron Light Source, Brookhaven
National Laboratory. Crystals were stabilized in mother liquor by stepwise
increasing glycerol concentration to 20% and then flash-frozen in liquid nitro-
gen. All diffraction data were processed using HKL2000 Suite (Otwinowski
and Minor, 1997). Molecular replacement solutions were obtained with
AMoRe (Navaza, 1994) using the FGFR2 kinase structure (PDB 2PVY; Chen
et al., 2007) as the search model. Rigid body refinements of the mutant
kinases were performed using the Crystallography & NMR System (Bru¨nger
et al., 1998) by treating the N lobe and C lobe of the kinases as two separate
entities. Model building was carried out using O (Jones et al., 1991), and
iterative positional and B factor refinements were completed using the
Crystallography & NMR System (Bru¨nger et al., 1998) or PHENIX (Adams
et al., 2010). Tight noncrystallographic restraints were applied throughout
the refinement cycles. Atomic superimpositions were made using lsqkab
(Kabsch, 1976) in the CCP4 Suite (Collaborative Computational Project,
Number 4, 1994), and structural representations were prepared using PyMOL
(DeLano, 2002).
Kinase Assay
Unphosphorylated WT, mono-phosphorylated FGFR2KpY657, and unphos-
phorylated pathogenic FGFR3 and FGFR2 kinases were mixed with kinase
reaction buffer containing ATP, MgCl2, and the substrate peptide to the final
concentrations of 13.5 mM (kinase), 262 mM (substrate), 10 mM (ATP), and
20 mM (MgCl2). The reactions were quenched at different time points by
adding EDTA to the reaction mix with the final concentration of 33 mM. The
progress of the substrate phosphorylation was monitored by native PAGE,
and the phosphate incorporation into the substrate peptide was quantified
by time-resolved MALDI-TOF mass spectrometry by comparing signals from
phosphorylated and the nonphosphorylated peptides as previously published
(Chen et al., 2008).
NMR Spectroscopy
The [1H,15N] HSQC spectrum of unphosphorylated FGFR2 kinase, harboring
the Ala648Thr mutation (FGFR2KA648T), was assigned using a triple-labeled
[2H,13C,15N] sample at 200 mM in a buffer consisting of 25 mM HEPES
(pH 7.5) and 150 mM NaCl. The rational for using this mutant rather than the
WT kinase was that the Ala648Thr, which is a pathogenic loss-of-function
mutation, increases the yield of protein expression. No significant chemical
shift perturbations were observed between unphosphorylated WT and the
Ala648Thr mutant FGFR2 kinases, so that the assignment could be transferred
unambiguously. A series of TROSY-based triple-resonance experiments
(HNCO, HN(CA)CO, HNCOCACB, and HNCACB) were carried out at 1H-fre-
quencies of 800 MHz using cryogenic probes allowing for the assignment of
81% of the non-Pro 1H-15N amide pairs. To ascertain the accuracy of the
assignments, FGFR2KA648T was selectively labeled with 15N-labeled amino
acids, including Tyr, Gly, Lys, Leu, Val, Phe, Ile, and Met. To compare the
effects of the pathogenic mutations and A loop phosphorylation on
the conformational dynamics of the FGFR2 kinase, samples of unphosphory-
latedWT FGFR2 kinase, mono-phosphorylated FGFR2KpY657, and pathogenic
FGFR2 kinases were 15N labeled and prepared at a concentration of300 mM.
All HSQC spectra were acquired with an 800 MHz spectrometer at 25C.
The assignments were transferred to the unphosphorylated WT, mono-phos-
phorylated FGFR2KpY657, and each of the mutant FGFR2 kinases. The most
significant perturbations were found to occur along a linear trajectory, and
therefore, the transfer of assignment was somewhat analogous to the peak
movement in fast exchange for a ligand titration. To quantify the chemical shift
perturbations between phosphorylated and unphosphorylated kinases, the
combined chemical shift (Dd) was calculated according to Equation 1:
Dd=
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ð0:154DdNÞ2 +Dd2H
q
(Equation 1)
DdN and DdH are the chemical shift changes between the unphosphorylated
and mono-phosphorylated samples for 15N and 1H-nuclei, respectively. The
residues displaying resolved linear chemical shift changes among the samples
were used to calculate the population of active state for each sample. We
assumed that the mono-phosphorylated kinase had an active state population
of 1.0, and the unphosphorylatedWT sample was a good approximation of the
ground state. Based on this, the population of active state (pactive) for each
mutant was calculated from the chemical shift positions (d) of the phosphory-
lated and unphosphorylated samples:
pactive =
dmutant  dphos
dunphos  dphos (Equation 2)
Residues in the aEF and aG helices showed small deviations from the linear
chemical shift trend, which were attributed to their proximity to the Lys659
substitutions in themutants and the phosphorylated Tyr657 in themono-phos-
phorylated FGFR2KpY657 (Figures 3 and S3).
ACCESSION NUMBERS
The Protein Data Bank (PDB) accession numbers for the coordinates and
structure factors of FGFR2 kinases harboring Lys659Asn, Lys659Met,
Lys659Glu, Lys659Gln, or Lys659Thr activating mutation reported in this
paper are 4J95, 4J96, 4J97, 4J98, and 4J99.
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